Why the study?
Does immunosuppressive therapy improve outcomes in patients with virus-negative inflammatory cardiomyopathy?
Does immunosuppressive therapy improve outcomes in patients with virus-negative inflammatory cardiomyopathy?
Immunosuppressive therapy is efficacious in treating virus-negative inflammatory cardiomyopathy, although a small subset of patients may not respond.
Supports immunosuppression as standard in virus-negative inflammatory cardiomyopathy; confirms RCT efficacy while highlighting 12% non-response for further study.
These data confirm the efficacy of immunosuppression in virus-negative inflammatory cardiomyopathy. Lack of response in 12% of cases suggests the presence of not screened viruses or mechanisms of damage and inflammation not susceptible to immunosuppression.
No takes yet. Share an insight, caveat, or question.
Frustaci et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: